311771-06-9

Basic information

• Product Name: 2-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-pentanoic acid ethyl ester
• Synonyms: 2-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-pentanoic acid ethyl ester
• CAS NO: 311771-06-9
• Molecular Weight: 451.486
• Mol File: 311771-06-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-pentanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-pentanoic acid ethyl ester(311771-06-9)
• EPA Substance Registry System: 2-[4-methoxy-3-(4-trifluoromethyl-benzylcarbamoyl)-benzyl]-pentanoic acid ethyl ester(311771-06-9)

Safety Data

• Hazardous Substances Data: 311771-06-9(Hazardous Substances Data)

Upstream product

• 3300-51-4 p-Trifluoromethylbenzylamine 
• 35051-49-1 2-diethoxyphosphoryl-pentanoic acid ethyl ester 
• 84923-70-6 5-formyl-2-methoxybenzoic acid 
• 311770-86-2 benzyl 5-formyl-2-methoxybenzoate 
• 311770-45-3 5-(2-ethoxycarbonyl-pentyl)-2-methoxy-benzoic acid 

Relevant articles and documents

Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators

Substituted phenylpropanoic acid derivatives were prepared as part of a search for subtype-selective human peroxisome proliferator activated receptor α (PPARα) activators. Structure-activity relationship studies indicated that the nature and the stereoche

SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR)

The invention provides novel substituted phenylpropanoic acid derivatives that activate by binding to receptor as ligands of human peroxisome preliferant-activated receptor α (PPARα), and exhibit potent decreasing action on lipids in blood (cholesterol and triglyceride). It relates to substituted phenylpropanoic acid derivatives represented by a general formula (1), their pharmaceutically acceptable salts and their hydrates, and processes for preparing them.